| Health / Medical Topics |
VEGFR2-targeted Contrast Agent BR55
A lipopeptide-based, vascular endothelial growth factor receptor 2 (VEGRF2) -targeted contrast agent with the property of molecular imaging of angiogenesis. BR55 is prepared by incorporation of a biospecific heterodimer peptide into the perfluorobutane-containing lipid-shelled microbubble membrane; the peptide specifically binds to VEGFR2 expressed on tumoral vascular endothelium allowing ultrasound imaging of the sites of active angiogenesis. (NCI Thesaurus)
YOU MAY ALSO LIKE
A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon…
An orally available ATP-competitive inhibitor of the vascular endothelial growth factor receptor type 2 (VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon…
A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor 1 (VEGFR1 or Flt-1) with potential immunostimulating, antiangiogenic, and…
An oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor…
An orally available small molecule dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) with…
A novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. VEGFR/FGFR…
